Implementation of a blood test for Alzheimer's disease in primary care: A pilot study
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract INTRODUCTION Blood biomarker (BBM) tests could improve early detection of Alzheimer's disease (AD), but their acceptability and feasibility in primary care (PC) are unclear. METHODS A BBM for AD pathology was offered to patients who screened positive for cognitive impairment in PC. Feasibility and acceptability were measured through rates of patient and provider consent and outcomes were assessed at 1 and 12 months post‐disclosure. RESULTS Two hundred thirty‐six patients were approached, 26 (22%) consented to BBM; 24 completed disclosures. BBM results showed 58% low, 7.7% intermediate, and 34.6% high likelihood of amyloid pathology. There were no changes in anxiety, depression, or distress at 1 month post disclosure. At 12 months, 5 (19.2%) were diagnosed with mild cognitive impairment, 3 (11.5%) with AD. Among 31 eligible PC providers, 53% consented to disclosure training and 26% completed disclosure. DISCUSSION BBM testing in PC is feasible but had limited uptake. Strategies to improve engagement are needed for implementation. Highlights This pilot study evaluated the use of a blood test for diagnosing Alzheimer's disease in primary care. Engagement with testing was limited in this real‐world setting. Testing was feasible and psychologically safe for patients. Future work should focus on strategies to improve patient and provider engagement
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Implementation of a blood test for Alzheimer's disease in primary care: A pilot study
- Date Crossref
- 01/01/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Regenstrief Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Indiana University School of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Indiana University – Purdue University Indianapolis pays non établi dans la noticeUniversité ou école supérieure
-
C2N Diagnostics (United States) pays non établi dans la noticeEntreprise
-
Indiana University Center for Aging Research Indianapolis Indiana USA pays non établi dans la noticeUniversité ou école supérieure
Regenstrief Institute, Indiana University School of Medicine et Indiana University – Purdue University Indianapolis, avec 2 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.